Loading…
Loading…
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company's stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%
Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
Bank of America Corp DE lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 71.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,302 shares of the biopharmaceutical company's stock after buying an additional 610,195 shares
Assenagon Asset Management S.A. decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 82.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,681 shares of the biopharmaceutical company's stock after selling 418,373 shares during the period. Assenagon Asset
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average rating of "Hold" from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average